Disguised Alpha   /   Compound references. Original research.
AniracetamResearch reference

Aniracetam / Study library

Research, with context.

Filter by study model, then open the original record to examine methods and findings.

3 studies shown

STUDY 01 · 2005
Receptor crystal structures and patch-clamp experiments

Mechanism of positive allosteric modulators acting on AMPA receptors

The investigators identified a binding site for aniracetam in the GluR2 ligand-binding domain. Mutations affecting that site disrupted modulation, supporting a relationship between the observed structure and receptor behavior.

Reading limit: This is mechanistic evidence from experimental receptor systems. It does not measure clinical benefit or long-term safety.

↗
STUDY 02 · 1987
Randomized, double-blind trial; 44 patients; three months

Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent

Both groups improved on some cognitive tests, but the clinical assessment found no efficacy difference between aniracetam and placebo. Confusion led to discontinuation in four aniracetam recipients and one placebo recipient.

Reading limit: This small, older trial concerns dementia, not healthy-user enhancement. A separate 1991 trial of 109 patients reported a different result.

Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study ↗
↗
STUDY 03 · 2014
Healthy adult mice; behavioral test battery

Aniracetam does not alter cognitive and affective behavior in adult C57BL/6J mice

Researchers found no significant group differences across tests of learning, memory, motor behavior, anxiety-related behavior, and repetitive behavior. The negative findings are relevant when claims extend from impaired models to healthy subjects.

Reading limit: A mouse result cannot settle human efficacy. It does show why benefits should not be assumed across models.

↗

How this guide was prepared

We reviewed the linked primary publications and source records for the claims summarized here. This is a focused educational selection, not a systematic review or a clinical recommendation. Scientific findings are kept separate from supplier catalog descriptions.

The selected research applies to the tested molecule, experimental model and conditions. It does not establish equivalent effects for a commercial formulation or support assumptions about clinical benefit or long-term safety.

Source index

Identity and product documentation

Confirm molecular identity, batch identification, analytical methods and the actual formulation before relating a commercial material to a publication. A purity percentage alone does not establish all of those facts.

Visit Disguised Alpha or read the extended compound profile.